ATNX vs. ATNM, ATOS, EPIX, CRMD, HOWL, NBTX, VIRX, IFRX, NXTC, and FBIO
Should you be buying Athenex stock or one of its competitors? The main competitors of Athenex include Actinium Pharmaceuticals (ATNM), Atossa Therapeutics (ATOS), ESSA Pharma (EPIX), CorMedix (CRMD), Werewolf Therapeutics (HOWL), Nanobiotix (NBTX), Viracta Therapeutics (VIRX), InflaRx (IFRX), NextCure (NXTC), and Fortress Biotech (FBIO). These companies are all part of the "pharmaceutical preparations" industry.
Athenex vs.
Athenex (NASDAQ:ATNX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
40.9% of Athenex shares are held by institutional investors. Comparatively, 8.9% of Actinium Pharmaceuticals shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Comparatively, 1.3% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Actinium Pharmaceuticals has lower revenue, but higher earnings than Athenex.
Athenex has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Athenex received 293 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 65.84% of users gave Athenex an outperform vote while only 0.00% of users gave Actinium Pharmaceuticals an outperform vote.
Athenex currently has a consensus price target of $4.00, indicating a potential upside of 645.99%. Given Athenex's higher probable upside, analysts plainly believe Athenex is more favorable than Actinium Pharmaceuticals.
Athenex has a net margin of -160.39% compared to Actinium Pharmaceuticals' net margin of -1,681.46%. Actinium Pharmaceuticals' return on equity of -32.44% beat Athenex's return on equity.
In the previous week, Athenex had 14 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 15 mentions for Athenex and 1 mentions for Actinium Pharmaceuticals. Athenex's average media sentiment score of 0.67 beat Actinium Pharmaceuticals' score of 0.00 indicating that Athenex is being referred to more favorably in the media.
Summary
Athenex beats Actinium Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart